Madrid

• A Study of Atezolizumab (Anti-PD-L1 Antibody) plus Bevacizumab versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellula … Ended recruitment
  2023-504303-86-00 5 2019-11-21 High-risk hepatocellular carcinoma (HCC)
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and … Ended recruitment
  2024-510626-89-00 5 2019-11-18 Non-Alcoholic Steatohepatitis (NASH)
• Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors Ended recruitment
  2023-506832-33-00 5 2019-11-06 haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibit
• Trimodality therapy with or without adjuvant Durvalumab to treat patients with bladder cancer Ended recruitment
  2024-512502-26-00 4 2019-11-06 Muscle-invasive bladder cancer
• A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in combination with best supportive … Ended recruitment
  2023-507443-10-00 5 2019-11-04 Patients with somatostatin receptor positive, well-differentiated G2 a
• EORTC 1740: Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Adjuvant Durvalumab ver … Ended recruitment
  2023-508853-13-00 4 2019-10-31 Oropharyngeal Squamous Cell Carcinoma
• Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme … Ended recruitment
  2023-508841-42-00 3 2019-10-30 Different types of advanced cancer
• This study will facilitate data collection of the long-term outcomes of pediatric subjects who have been treated in clinical trials with dab … Ended recruitment
  2023-509276-42-00 6 2019-10-30 Children and Adolescents with Cancers Harboring V600 mutation.
• Efficacy Study of Nivolumab Compared to Placebo in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIB/C Melanoma (Ch … Ended recruitment
  2022-502354-14-00 5 2019-10-28 Completely resected Stage IIb/c melanoma
• Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended recruitment
  2024-510776-20-00 5 2019-10-25 Female or male patients with histologically confirmed HR-positive, HER
• A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged … Ended recruitment
  2023-507678-42-00 6 2019-10-24 Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Br
• This is a randomized, double-blind, controlled trial to evaluate the efficacy and safety of cabozantinib in combination with nivolumab and i … Ended recruitment
  2024-515616-47-00 5 2019-10-03 Metastatic Renal Cell Carcinoma
• Dose Escalation and Dose Expansion Study of PD1-LAG3 Bispecific Antibody in Patients with Advanced and/or Metastatic Solid Tumors Ended recruitment
  2023-503425-18-00 1 2019-10-02 Metastatic Solid Tumors
• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Ended recruitment
  2023-508526-10-00 7 2019-10-01 Malignant solid tumors: Patients with relapsed or refractory, advanced
• A Phase 3 clinical study to investigate the effects of BAN2401 in patients with Early Alzheimer's Disease. Ended recruitment
  2024-510887-22-00 5 2019-09-30 Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
• A trial to learn if different cancer treatment combinations are safe and work in people with advanced non-small cell lung cancer that has mu … Ended recruitment
  2023-504624-25-00 4 2019-09-26 Advanced Non-Small Cell Lung Cancer
• A Phase 3, Randomized, Double-blind Study of Chemotherapy plus Nivolumab versus Chemotherapy plus Placebo provided before surgery, followed … Ended recruitment
  2022-502658-15-00 5 2019-09-22 Resectable Stage II-IIIB Non-small cell lung cancer
• A phase II trial of MK-3475 (pembrolizumab) in children and young adults with classical Hodgkin lymphoma Ended recruitment
  2023-504821-38-00 4 2019-09-19 Classical Hodgkin lymphoma in children and young adults
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended recruitment
  2023-505980-36-00 5 2019-09-19 Primary progressive multiple sclerosis (PPMS)
• EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER Ended recruitment
  2024-514604-14-00 4 2019-09-18 Muscle-invasive bladder cancer
• An efficacy and safety study of 2-OHOA in patients with glioblastoma Ended recruitment
  2024-511542-39-00 10 2019-09-16 Newly diagnosed primary glioblastoma multiforme (ndGBM)
• Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Stu … Ended recruitment
  2023-505321-14-00 10 2019-09-06 Warm Autoimmune Hemolytic Anemia
• A study to learn if combination pyrimidine nucleosides is safe, how well it works and how it moves through the bloodstream in participants w … Ended recruitment
  2023-510427-29-00 4 2019-09-04 Thymidine kinase 2 deficiency

Showing 2,449–2,472 of 3,550 trials